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In Brief
Saddawi-Konefka et al. show that the
transcription factor nuclear factor
erythroid-derived 2-like 2, or Nrf2,
induces the cytokine interleukin-17D.
Nrf2/IL-17D-mediated natural killer cell
recruitment can lead to the regression of
established tumors. Therefore, inducing
IL-17D using Nrf2 agonists has potential
for cancer immune therapy.
Cell Reports
ArticleNrf2 Induces IL-17D to Mediate Tumor
and Virus Surveillance
Robert Saddawi-Konefka,1,4 Ruth Seelige,1,4 Emilie T.E. Gross,1 Eric Levy,2 Stephen C. Searles,1 Allen Washington, Jr.,1
Endi K. Santosa,1 Beichen Liu,1 Timothy E. O’Sullivan,3 Olivier Harismendy,2 and Jack D. Bui1,5,*
1Department of Pathology, University of California, San Diego, San Diego, CA 92093, USA
2Moores Cancer Center Oncogenomics Laboratory, University of California, San Diego, San Diego, CA 92093, USA
3Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
4Co-first author
5Lead Contact
*Correspondence: jbui@ucsd.edu
http://dx.doi.org/10.1016/j.celrep.2016.07.075SUMMARY
Cells undergoing xenobiotic or oxidative stress acti-
vate the transcription factor nuclear factor erythroid-
derived 2-like 2 (Nrf2), which initiates an intrinsic
‘‘stress surveillance’’ pathway. We recently found
that the cytokine IL-17D effects a form of extrinsic
stress surveillance by inducing antitumor immunity,
but how IL-17D is regulated remains unknown.
Here, we show that Nrf2 induced IL-17D in cancer
cell lines. Moreover, both Nrf2 and IL-17D were
induced in primary tumors as well as during viral
infection in vivo. Expression of IL-17D in tumors
and virally infected cells is essential for optimal pro-
tection of the host as il17d/ mice experienced a
higher incidence of tumors and exacerbated viral in-
fections compared to wild-type (WT) animals. More-
over, activating Nrf2 to induce IL-17D in established
tumors led to natural killer cell-dependent tumor
regression. These data demonstrate that Nrf2 can
initiate both intrinsic and extrinsic stress surveillance
pathways and highlight the use of Nrf2 agonists as
immune therapies for cancer and infection.INTRODUCTION
Cells undergoing malignant transformation or viral infection
constitute cells in a ‘‘stressed state,’’ characterized by altered
metabolism and imbalanced reactive oxidative species (ROS)
(Gorrini et al., 2013; Martindale and Holbrook, 2002; Schwarz,
1996). In order to deal with ROS, cells activate the transcription
factor nuclear factor erythroid-derived 2-like 2 or Nfe2l2 (Nrf2).
Nrf2 is amember of the cap ‘‘n’’ collar family of bZip transcription
factors and is recognized as the primary responder to cellular
oxidative stress (Ma, 2013). Nrf2 induces genes involved primar-
ily in antioxidant defense, oxidant signaling, and drug meta-
bolism, and secondarily, in metabolism, cell proliferation, and
proteasome activity (Malhotra et al., 2010; Scha¨fer et al., 2012;
T€urei et al., 2013).2348 Cell Reports 16, 2348–2358, August 30, 2016 ª 2016 The Autho
This is an open access article under the CC BY license (http://creativeThe cell-protective pathways induced by Nrf2 can have
opposing effects on cancer development. For example, Nrf2
protects somatic and premalignant cells from carcinogens
and, in this context, fulfills a tumor suppressor role (Kensler
and Wakabayashi, 2010; Ma and He, 2012). On the other hand,
it is well-documented that Nrf2 can promote the growth and sur-
vival of established tumors by inducing anti-oxidative pathways
that help cancers deal with chronic oxidative stress, a hallmark of
cancer progression (Jaramillo and Zhang, 2013; Sporn and Liby,
2012). It is not known whether Nrf2 regulates extrinsic stress
response mechanisms that operate to suppress carcinogenesis.
Recently, our group identified the cytokine IL-17D as a mole-
cule expressed at higher levels in highly immunogenic tumor
cells compared to poorly immunogenic tumor cells (O’Sullivan
et al., 2014; Saddawi-Konefka et al., 2015). When IL-17D was
overexpressed in poorly immunogenic cancer cells, it led to im-
mune rejection mediated by natural killer (NK) cells. The regula-
tion of IL-17D is not known, but based on its tumor rejection
activities, we hypothesize that IL-17D would initiate tumor sur-
veillance and thus accompany early cellular transformation.
Here, we show direct and compelling evidence that Nrf2 in-
duces the expression of IL-17D, therefore initiating antitumor
immune responses. We also find that viral infection induces
Nrf2 and IL-17D, presumably by causing local oxidative stress.
The induction of IL-17D is required for effective cancer surveil-
lance and antiviral responses, as mice deficient in IL-17D had
increased formation of MCA-induced tumors and exacerbated
pathology when infected with vaccinia virus (VV) or murine cyto-
megalovirus (MCMV). Our data document a link between cellular
oxidative stress—resulting from viral infection or tumorigen-
esis—and the initiation of immunity. Moreover, our results define
an immune activating role for the well-studied factor Nrf2, which
has not been previously defined. This role for Nrf2 in inducing IL-
17D has therapeutic benefit in our mouse models.RESULTS
Nrf2 Induces IL-17D
To explore IL-17D regulation, we performed a transcription fac-
tor binding site (TFBS) analysis of the promoter and intronic re-
gions of the human and mouse il17d genes (Figure 1A). Ourr(s).
commons.org/licenses/by/4.0/).
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Figure 1. The Transcription Factor Nrf2 Induces IL-17D
(A) Consensus sequence analysis of Nrf2 TFBS in the promoter and intronic regions of human and mouse il17d genes. Green highlights represent Nrf2 binding
sites in (D).
(B) H2O2 activates Nrf2 and induces il17d in MEFs (left) and MCA-induced sarcoma (right).
(C) Pharmacologic activation of Nrf2 with tBHQ induces il17d in the murine melanoma B16 (left) and human Burkitt’s lymphoma cell line Ramos (right).
(D) ChIP of B16 melanoma cells treated with tBHQ shows that Nrf2 directly binds to chromatin upstream of the il17d gene (regions around 4196, 4860 (left), and
3730 bp (right) upstream of the il17d start site). Values are expressed as the % of Nrf2 bound in immunoprecipitated samples compared to input samples.
(E) siRNA to nrf2 prior to activation with H2O2/tBHQ in tumor cell lines blocks the induction of il17d in MCA sarcoma (left) or B16 melanoma (right). TFBS,
transcription factor binding site.
Experiments repeated at least twice. Error bars represent ± SEM. See also Figure S1 and Tables S1 and S3.analysis revealed several putative Nrf2 binding sites, defined as
anti-oxidant responsive elements (ARE) (Nguyen et al., 2003)
(Figure 1A; Table S1). Given the abundance of ARE in promoter
and intronic regions of il17d, we hypothesized that the activation
of Nrf2 would induce IL-17D. To test this, we treated murine em-
bryonic fibroblasts (MEFs) and the 3-methylcholanthrene (MCA)-
induced sarcoma cell line F244 (O’Sullivan et al., 2012; Shan-
karan et al., 2001) with H2O2, a known activator of Nrf2 (Pergola
et al., 2011; Tkachev et al., 2011) (Figure 1B). H2O2 treatment led
to significant, time-responsive increases in the transcript of
il17d. Similarly, activation of Nrf2 with tert-butylhydroquinone
(tBHQ) resulted in the increase of il17d transcript in the murine
melanoma cell line B16, the human Burkitt’s lymphoma cell
line Ramos, and in theMCA-induced sarcoma cell line F244 (Fig-
ures 1C and S1A).
Next, we determined whether the transcription factor Nrf2
directly binds to the TFBS we identified in our analysis of the
il17d gene. We performed a chromatin immunoprecipitation fol-lowed by PCR amplification of specific sequences (ChIP-qPCR)
in tBHQ-treated or control-treated B16 cell lines. Cells were fixed
and sonicated before immunoprecipitation with Nrf2-specific
antibody or control IgG. Fractionation and western blot analysis
confirmed that Nrf2 preferentially accumulated in the nuclear
fraction of treated cells (not shown). qPCR analysis of ChIP frac-
tions revealed two sites upstream of the il17d start site where
Nrf2 has significant binding following activation (Figure 1D).
These two binding sites for Nrf2 corresponded to Nrf2 target
ARE elements identified at 4195, 4860, and 3730 bp upstream
of the il17d start site (Figure 1A; Table S1). qPCR analysis of
the known gene target for Nrf2, heme oxygenase 1 (hmox1),
also indicated Nrf2 binding following tBHQ treatment in the
B16 cell line (Figure S1B).
TFBS analysis with the ENCODE UCSC browser revealed that
other transcription factors might bind and regulate IL-17D (data
not shown), indicating that Nrf2 may not be wholly responsible
for the induction of IL-17D. In order to examine the necessity ofCell Reports 16, 2348–2358, August 30, 2016 2349
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Figure 2. Nrf2 Is Activated in Primary Murine Tumors, and Its Activation Correlates with the Expression of il17d in Human Cancers
(A) Expression of nrf2, hmox1, il17d, and keratin in primary MCA-induced sarcomas (n = 9) assessed via qPCR and compared to normal untreated skin (n = 6).
(B) Expression of il17d in all available TCGA human cancers correlates with the expression of ARE-containing genes.
(C) MCA-induced sarcomas grouped according to their growth phenotype in WT mice (n = 3 per group) show correlations in their expression of il17d transcript
and Nrf2 protein.
Experiments repeated at least twice. Error bars represent ± SEM. See also Figure S2.Nrf2 for the induction of IL-17D, we activated Nrf2 in the F244 or
B16 cell lines in the presence of siRNAspecific to nrf2 (Figures 1E,
S1C, and S1D) and in F244 and B16 cell lines bearing a stable
knockdown of nrf2 via small hairpin RNA (shRNA) (Figures S1E–
S1J). Knockdown of Nrf2 in B16 and F244 (80%, Figures
S1C–S1F) was sufficient to block the induction of il17d following
activation of Nrf2 with either H2O2 or tBHQ. Altogether, we found
that Nrf2 not only directly bound to the il17d promoter region but
also was required for efficient induction of il17d by oxidative
stress.
Nrf2 and IL-17D Are Co-expressed in Primary Tumors
and during Viral Infection
To determine the relevance of the Nrf2 regulation of IL-17D
in vivo, we examined the expression of IL-17D, Nrf2, and its
known target genes in primary human and mouse tumors.
Analyzing gene expression in primary MCA-induced tumors
(from Figure 4A) revealed that nrf2, its target hmox1, and il17d
were upregulated compared to normal untreated skin samples
(Figure 2A). Using data sourced from The Cancer Genome Atlas
(TCGA), we found that il17d expression directly correlated with
the expression of ARE-containing Nrf2 targets (signature of
nine genes in total, see the Experimental Procedures) across
all available human cancers (n = 9,755) (Figure 2B). The results
are not significant (p = 0.07), likely due to the fact that TCGA
data include many tumors harvested at late time points, when
we hypothesize il17d and nrf2 expression to be uncoupled
due to editing of IL-17D (O’Sullivan et al., 2014). Moreover, infil-
trated immune cells that have a different gene expression profile
can influence the results (Aran et al., 2015). We also found that a
high level of IL-17D expression in 13 out of 31 human cancer
types confers a survival advantage (Table S2), representatively
shown for brain lower grade glioma and ovarian serous cystade-
nocarcinoma (Figure S2A). Additionally, an analysis of our MCA-
sarcoma tumor cell lines demonstrated that Nrf2 and il17d are
co-expressed in murine tumor cell lines (Figure 2C). Matching
our previous data (O’Sullivan et al., 2014; Saddawi-Konefka
et al., 2015), cell lines expressing high levels of IL-17D tended
to behave as regressors, now underlined by their co-expression
of Nrf2. Together, these data suggest that Nrf2 regulates IL-17D2350 Cell Reports 16, 2348–2358, August 30, 2016during primary tumor formation in both human and mouse sys-
tems in order to initiate productive antitumor immune responses
leading to tumor regression and prolonged survival. IL-17D
expression only correlates with better survival in a fraction of hu-
man cancers (Figure S2; Table S2), suggesting that its regulation
might be context-dependent and underlining the importance of
analyzing its regulation in defined in vivo mouse models.
Viral infections represent another sort of cellular stress.
Because IL-17D recruits NK cells that can mediate antiviral re-
sponses, we sought to examine the role of the Nrf2-IL-17D
axis in antiviral immunity. First, we measured Nrf2 and IL-17D
following vaccinia virus (VV) and murine cytomegalovirus
(MCMV) infection. In vitro, we observed an increase in the tran-
script levels of il17d in both infected primary-derived fibroblasts
and tumor cell lines (Figures 3A and 3B). The results in the tumor
cell lines are not significant, likely due to the fact that tumors are
not the primary target for viruses. For in vivo analysis, we scari-
fied WT mice with VV. Tissue harvested from these mice had
increased expression of il17d and Nrf2 (Figures 3C and 3D;
see Figures S3A and S3B for an example of VV scar). To model
the local activation of Nrf2 and IL-17D in vivo, we adapted a sys-
tem in which we topically applied tBHQ onto the dorsal flanks of
mice (Scha¨fer et al., 2014). Mice treated topically with tBHQ had
increased transcript and protein levels of il17d and Nrf2, respec-
tively, commensurate with those observed following infection by
scarification (Figures 3E and 3F). Together, these results suggest
that the Nrf2-IL-17D regulatory axis is activated during primary
tumorigenesis and viral infection in order to confer protection
from disease progression.
IL-17D Protects the Host from Primary Tumorigenesis
and Viral Infection
We previously showed that IL-17D can mediate tumor rejection
when overexpressed in cancer cells (O’Sullivan et al., 2014),
but its endogenous role in cancer immunosurveillance had not
been demonstrated. Therefore, we compared the development
of primary tumors in WT versus il17d/ mice, each treated
with the carcinogen 3-methylcholanthrene (MCA). Because the
immune cellularity of il17d/ mice has not been studied, we
first immune-phenotyped these mice. We found that the major
Figure 3. The Expressions of il17d and Nrf2
Correlate following Viral Infection
(A) Primary-derived adult fibroblasts infected with
vaccina virus (VV) or mouse cytomegalovirus
(MCMV) show an increase in the transcript of il17d.
(B) An MCA sarcoma or B16 melanoma cell line
increases il17d transcript following VV infection
in vitro.
(C) Infection by scarification with VV in vivo
leads to an increase in il17d and nrf2 transcript
expression.
(D) IHC for Nrf2 protein in infected versus non-in-
fected scars show an increase in Nrf2 protein
expression in skin spanning dermis to epidermis.
Scale bar, 200 mm.
(E) Topical application of tBHQ on the flank in vivo
increases il17d and nrf2 transcript expression.
(F) Nrf2 protein expression is similarly increased
following tBHQ topical applications.
Experiments repeated at least twice. Error bars
represent ± SEM. See also Figure S3.immune populations in the spleen, lymph node, bone marrow,
and bloodwere similar betweenWT and il17d/mice (Figure S4
and data not shown). Despite demonstrating a largely normal
immune system at baseline, strikingly, il17d/mice were signif-
icantly more susceptible to the development of primary tumors
(Figure 4A). At a 25-mg dose of MCA, approximately twice the
number of il17d/ mice compared to WT mice developed
primary tumors. At a 5-mg dose of MCA, WT mice are largely
tumor-free, whereas 40% of il17d/ mice developed primary
tumors. These findings confirm that, similar to Nrf2, the cytokine
IL-17D can protect the host from primary carcinogen-induced
tumor formation.
Because we found Nrf2 and IL-17D to be induced after viral
infection, we next tested the role of IL-17D in viral infection.
Following infection of WT and il17d/ animals, we observed
an exacerbation of the VV scar in il17d/ animals compared
to WT animals at two doses (Figure 4B). Similarly, il17d/
mice were more susceptible to another virus, MCMV, displayed
as an increase in weight loss after systemic infection (Figure 4C).
To test whether IL-17D can directly inhibit viral replication or pro-
gression, we infected either parent or IL-17D-expressing tumor
cell lines with VV (Figure S3C). Expression of IL-17D in vitro did
not protect cells from infection, suggesting that IL-17D’s role in
protecting the host from viral infection may require the immune
system. These findings imply that virus infection may activate
the Nrf2-IL-17D axis to initiate surveillance and contribute to
host antiviral defense.Cell RepActivating Tumor-Intrinsic Nrf2
Delays Tumor Growth In Vivo via
Induction of Tumor-Derived IL-17D
Having shown a requirement for IL-17D in
effective tumor surveillance (O’Sullivan
et al., 2014; Saddawi-Konefka et al.,
2015) (Figure 4A), we hypothesized that
activating Nrf2 in vivo would induce IL-
17D in established tumors, which in turn
would initiate protective immunosurveil-lance. To examine this, tumor-bearing mice were treated topi-
cally with tBHQ or lanolin control cream beginning when tumors
achieved an average diameter of 3 mm.We found that treatment
with tBHQ delayed tumor growth in WT mice bearing F244 or
B16 tumors (Figures 5A and 5B). Moreover, tBHQ led to the
in vivo induction of both hmox1 and il17d in tumors derived
from both transplanted cell lines (Figure 5C).
Recognizing that tBHQ could induce Nrf2 in both host and tu-
mor cells and that Nrf2 might induce targets other than IL-17D,
we wanted to examine: first, whether tBHQ is activating Nrf2
and IL-17D in tumor cells versus host cells; second, whether
tBHQ necessarily and specifically induces IL-17D to mediate tu-
mor regression; and third, whether Nrf2 is required to induce IL-
17D and delay tumor growth. Therefore, we transplanted nrf2/
and il17d/mice with B16 and treated with tBHQ. We observed
delayed tumor growth of B16 in nrf2/ and il17d/ mice (Fig-
ures 5D and 5E), demonstrating that host expression of nrf2 or
il17d is not required for the response to tBHQ.
To examine the role of tumor-derived IL-17D during tBHQ-
induced tumor rejection, we utilized an MCA sarcoma cell
line that we generated from an il17d/ host (named F38K1;
derived from the MCA experiment in Figure 4A). Based on
established definitions for tumor growth phenotypes (O’Sullivan
et al., 2012), we classified F38K1 as a progressor tumor (Fig-
ure S5A). We confirmed F38K1’s sensitivity to Nrf2 activation
by stimulating the cell line in vitro and measuring hmox1 tran-
script expression, which increased in the presence of tBHQorts 16, 2348–2358, August 30, 2016 2351
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Figure 4. IL-17D Protects from Primary
Tumorigenesis and Viral Infection
(A) Primary tumors induced with the carcinogen
3-MCA in il17d/ versusWTmice develop tumors
at a higher frequency at low (5 mg, left) and high
doses (25 mg, right) of carcinogen.
(B) Scars infected with VV in il17d/ mice are
larger than in WT before scar resolution at both a
lower (10
^5, left) and higher pfu (10
^6, right).
(C) Il17d/ mice i.p. infected with 3 3 105 pfu
MCMV are more susceptible than WT mice, as
measured by weight loss.
Experiments repeated at least twice. Error bars
represent ± SEM. See also Figures S3 and S4.(Figure S5B). In vivo, tBHQ treatment in WT (Figure 5F) and
il17d/ (Figure S5C) mice transplanted with F38K1 failed to
delay tumor growth. This finding implies that the antitumor
response resulting from the activation of Nrf2, via topical appli-
cation of tBHQ, requires tumor-expressed IL-17D and not the
many previously described targets of Nrf2 (Malhotra et al.,
2010; T€urei et al., 2013).
To analyze the requirement of tumor-derived Nrf2 during
tBHQ-induced tumor rejection, we generated independent sar-
coma and melanoma cell lines bearing a stable knockdown of
nrf2 via shRNA (Figures S1E–S1J). We chose the two shRNA
constructs that showed the best downregulation of nrf2 (90%
and 83% for F244 sarcoma; 88% and 80% for B16 melanoma)
for further experiments. tBHQ treatment had no influence on
in vitro cell growth in any of the transduced cell lines (Figures
S5D and S5E and not shown). When transplanted into WT
mice, tBHQ treatment failed to delay tumor growth of the two
nrf2 knockdown cell lines (Figures 5G and 5H and data not
shown), in contrast to the shRNA control cell lines (Figure S5F).
Moreover, the tBHQ-mediated induction of il17d (and hmox1)
was abolished in vivo when nrf2 was knocked down (Figure 5I).
These results show that tumor-derived Nrf2 is required for both
the tBHQ-dependent induction of il17d as well as the rejection
of established tumors. It should be noted that silencing nrf2 in
these progressor tumors actually caused them to display growth
delay compared to the parental cells (Figures 5G and 5H and not2352 Cell Reports 16, 2348–2358, August 30, 2016shown). These results indicate that Nrf2
may have tumor promoting activity and
thus, the tumor rejection by tBHQ-induc-
tion of IL-17D must be stronger than the
tumor promoting activity of Nrf2.
Activating Nrf2 Mediates Tumor
Rejection via Recruitment of NK
Cells
To determine whether the immune sys-
tem was required for the antitumor effect
of Nrf2 agonists, we transplanted B16
melanoma cells into immune-deficient
mice: rag2/, which lack adaptive immu-
nity but possess intact NK cells and mac-
rophages (Shinkai et al., 1992) and
rag2/ gc/, which lack adaptive im-
munity as well as NK cells (Mazurier et al., 1999). Notably, we
found that topical treatment of tumors with tBHQ delayed tumor
growth in rag2/ but not rag2/ gc/ (Figures 6A and 6B). This
suggests that NK cells are the immune population responsible
for tBHQ-mediated tumor rejection. To identify the immune cells
recruited by tBHQ treatment, we harvested B16 tumors after
7 days of treatment (representative image shown in Figure 5A)
and performed a fluorescence-activated cell sorting (FACS)
analysis of tumor infiltrating leukocytes (TILs). Our TIL analysis
revealed an increase in the percentage and total number of infil-
trating NK cells when tumors were treated with tBHQ (Figures
6C–6E), a result consistent with our prior study showing that
IL-17D recruited NK cells via induction of the chemokine CCL2
(O’Sullivan et al., 2014; Saddawi-Konefka et al., 2015). No other
TIL populations were found to be different in treated versus un-
treated tumors (Figure 6C).We next investigated the requirement
of Nrf2 and IL-17D for the recruitment of NK cells. When nrf2was
knocked down or il17d was deleted within the tumor cell (by
transplanting the cell line F38K1), the tBHQ-mediated increase
in NK cells was abolished (Figure 6F). NK cells in tumors did
not differ in activation or function (as assessed by expression
of CD69, IFNg, and Granzyme B) (Figure S5G). Together, our re-
sults show that NK cells are recruited into tBHQ-treated tumors
and that tumor-expressed Nrf2 and IL-17D are required for the
tBHQ-mediated recruitment of NK cells. In order to assess if
il17d expression correlated with NK cell infiltration in human
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Figure 5. Activating Nrf2 Induces IL-17D and Delays Tumor Growth In Vivo
Tumor cells were transplanted subcutaneously and allowed to reach an established size (33 3 mm) before the initiation of topical treatments with tBHQ once
daily for 7 days.
(A and B) When transplanted in WT hosts, B16 (A) and F244 (B) regress following tBHQ treatment.
(C) Il17d and the Nrf2 target gene hmox1 are upregulated in B16 and F244 tumors treated with tBHQ.
(D and E) Topical treatments with tBHQ delay the growth of B16 when transplanted into nrf2/ (D) and il17d/ (E) mice.
(F) Topical tBHQ fails to induce the regression of il17d/ MCA sarcoma cells transplanted into WT mice.
(G and H) tBHQ treatment fails to delay tumor growth when nrf2 is knocked down via shRNA in B16 melanoma (G) or F244 sarcoma cells (H).
(I) Il17d and the Nrf2 target gene hmox1 are not induced in B16 and F244 tumors treated with tBHQ after nrf2 knockdown.
Experiments repeated at least twice with no fewer than ten mice. Error bars represent ± SEM. See also Figure S5.cancer, we used the Z scores from RNA sequencing (RNA-seq)
of four NK-cell-expressed genes from TCGA to approximate
the presence of NK cells in human skin cutaneous melanoma
and sarcoma (Figure S6A). We found no positive correlation,
probably due to the fact that TCGA data represent chronic rather
than acute induction of IL-17D as assessed in our mouse model.
The same held true for the correlation of il17d with NK- and
macrophage-recruiting gene products (CCL5 and CCL2, Figures
S6B and S6C) as well as NK cell-expressed genes NKG2D
and NKP46 (Figures S6D and S6E). This does not exclude a
role for Nrf2 and IL-17D in NK cell recruitment in human cancers,
but rather calls for a more detailed analysis of human cancer
biopsies after acute induction of IL-17D. To date, this is notpossible but might be done in the future if tBHQ or another
Nrf2 agonist reaches clinical trials.
DISCUSSION
In this study, we have demonstrated an obligate role for IL-17D in
effective tumor surveillance, optimal antiviral responses, and
cancer immune therapy via Nrf2 agonists. It is well established
that immune responses to viruses and transformed cells have
overlapping features (Raulet and Guerra, 2009): both involve
NK cells, Th1 immunity, and CD8+ T cells. Moreover, NKG2D li-
gands are induced by viral infection (Shafi et al., 2011; Vivier
et al., 2011) as well as being constitutively expressed on cancerCell Reports 16, 2348–2358, August 30, 2016 2353
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Figure 6. Inducing Nrf2 via tBHQ Leads to the Recruitment of NK Cells into Tumors
(A and B) tBHQ delays the growth of B16 tumors when transplanted into Rag2/ (A) but not Rag2/x gc/ (B) hosts.
(C–E) Topical treatment of B16 melanomas with tBHQ increases the percentage (C–E) and total number (E) of NK cells present in tumors, while other immune
populations remain unchanged (C).
(F) The tBHQ-induced increase in NK cell recruitment is prevented when nrf2 is knocked down or il17d is deleted (F38K1) in tumors.
Experiments repeated at least twice. Error bars represent ± SEM. See also Figures S4–S6.cells (Diefenbach et al., 2001; Guerra et al., 2008). As such, our
finding that IL-17D is induced by viral infection and expressed
constitutively by immunogenic cancer cells has precedence in
principle and data.
We have definitively shown that Nrf2, an oxidative stress
response factor, can function as a tumor suppressor via direct in-
duction of IL-17D. A tumor suppressor role for Nrf2 is supported
by previous studies showing that mice genetically deficient in
Nrf2 are more susceptible to a wide range of carcinogen-
induced cancers (for review, seeMa andHe, 2012). For example,
nrf2/mice displayed increased incidence of forestomach can-
cer (Ramos-Gomez et al., 2003) and bladder cancer (Iida et al.,
2004) induced by carcinogens known to induce oxidative stress.
Nrf2/mice also had increased skin cancer in a model of sulfo-
raphane-mediated protection fromDMBA/TPA induced carcino-
genesis (Xu et al., 2006). There are no studies to addresswhether
Nrf2 participates in tumor immunosurveillance in any of these
model systems. Importantly, cancer immunoediting and tumor
elimination have been extensively documented in mousemodels2354 Cell Reports 16, 2348–2358, August 30, 2016of MCA-induced sarcomas, and it was recently shown that MCA
can acutely induce Nrf2 and its target genes in liver after 24 hr
(Jin and Dong, 2013). Accordingly, we show that Nrf2, its target
genes and IL-17D are induced in MCA tumors. We suggest that
Nrf2 can mediate anti-cancer functions by inducing immune-
dependent pathways, namely the IL-17D-dependent recruit-
ment of NK cells.
In contrast to the tumor suppressor role of Nrf2, other studies
have shown that Nrf2 expression in tumor cells can promote their
survival in the face of oxidative stress, hypoxia, and/or chemo-
therapy (Jaramillo and Zhang, 2013; Sporn and Liby, 2012). In
fact, Nrf2 blockade has become an anti-cancer approach since
certain cancer cells (and model systems) report oncogene-
induced, constitutive Nrf2 activity as associated with tumor
growth and metastasis (DeNicola et al., 2011; Shelton and
Jaiswal, 2013). These studies have prompted a re-evaluation
of the role of Nrf2 in cancer and support a model whereby Nrf2
is a ‘‘double-edged sword’’ that can suppress or promote can-
cer. Notably, a recent study found that Nrf2 acts early in
tumorigenesis to suppress tumor formation and later-on to pro-
mote tumor formation (Satoh et al., 2013). We propose that Nrf2-
mediated induction of IL-17D activates antitumor immunity at an
early stage to eliminate the tumor before Nrf2 exerts its pro-tu-
mor activity. This early immune pressure mediated by NK cells
could lead to cancer immunoediting, resulting in the loss of IL-
17D expression as an immune evasion mechanism. Therefore,
the expression of IL-17D in late stage human cancers may not
always correlate with good prognosis or NK cell infiltration, as
shown in Table S2 and Figures S2B, S2C, and S6. In fact, given
the known tumor promoting roles of Nrf2, late stage human can-
cers that display chronic inflammationmay express high levels of
Nrf2 without incurring the antitumor responses that could be
mediated by IL-17D and/or NK cells. Thus, it will be important
to determine if acute induction of Nrf2 in human cancer can
indeed serve as a therapeutic mechanism to induce IL-17D
and/or recruit NK cells to mediate antitumor immune responses.
We have implicated that Nrf2 agonists, some of which are
currently in clinical trials, would be highly efficacious inducers
of cancer immunosurveillance and immune therapy by acutely
inducing IL-17D. Further studies are needed to determine
whether Nrf2 agonists can be used to treat a broad range of es-
tablished human tumors and/or prevent the development of can-
cer. It will be important to cast a broad and deep net in these
studies, as it is likely that the role of the Nrf2-IL-17D pathway
in tumor progression is context-dependent. Notably, our data
suggest that the clinical use of antioxidants to prevent cancer
and promote overall health may inadvertently limit Nrf2 induction
and attenuate an endogenous tumor surveillance pathway. On
the other hand, judicious use of oxidative species may find a
niche in immunotherapy. For example, drugs such as tBHQ,
which do not induce ROS but can directly induce the Nrf2-IL-
17D pathway may have even higher efficacy as they would acti-
vate an endogenous tumor surveillance pathway without pro-
ducing genotoxic ROS.
The role of other IL-17 family members in cancer is still contro-
versial. For the most studied member, IL-17A, tumor-promoting
roles (Charles et al., 2009; Nam et al., 2008; Numasaki et al.,
2003), antitumor functions (Benatar et al., 2008; Benchetrit
et al., 2002; Muranski et al., 2008), and immune cell recruiting
roles (Martin-Orozco et al., 2009) have all been documented.
Specifically, an antitumor role in humans was shown whereby
IL-17A production correlated with CD8+ T cell and CD57+ NK
cell presence in esophageal squamous cell carcinomas (Lv
et al., 2011) and was associated with the induction of T cell-,
NK cell- and DC-attracting chemokines (Lu et al., 2013). On
the other hand, a pro-tumor role for IL-17A was shown in breast
cancer whereby neutralizing IL-17A with antibodies reduced
chemokine expression and thereby breast cancer cell migration
and metastasis (Roy et al., 2014). Although we have only defined
antitumor activities for IL-17D, the fact that Nrf2 can induce IL-
17Dmight suggest that IL-17D could also have tumor promoting
activities, similar to IL-17A. This could certainly limit therapies
based on IL-17D.
We also found that IL-17D is induced by viral infection and is
required for optimal antiviral responses. The IL-17 family of cyto-
kines has been characterized as essential to antimicrobial host
defense (for reviews, see Gaffen, 2011; Gu et al., 2013; Iwakuraet al., 2011; Jin and Dong, 2013). Specifically, IL-17C and IL-
17A/F are thought to mediate anti-bacterial and anti-fungal re-
sponses via recruitment of neutrophils. IL-17E contributes to
anti-helminth responses via recruitment of eosinophils. Our
finding that IL-17D is induced during viral infection, recruits NK
cells, and is required for optimal responses to VV and MCMV
infection, suggests that the IL-17 family may have evolved to
mediate distinct and specific anti-pathogen responses. Given
the ancient origin of the IL-17 family, it is tempting to speculate
that IL-17D and IL-17C were the first family members to evolve
to mediate local control of pathogen infection prior to the evolu-
tion of adaptive immunity.
To date, the signals that induce and maintain Nrf2 activity dur-
ing carcinogenesis are still unclear. We speculate that during tu-
mor formation, Nrf2 activation occurs acutely due to carcinogen
exposure, is maintained subacutely by oncogenes, and can be
detected constitutively in advanced cancers by mutation or in-
flammatory cells providing an oxidative burst. Indeed, previous
studies have found that MCA induced Nrf2 and its target genes
acutely (Jin et al., 2014), in line with our finding that MCA induced
Nrf2 and IL-17D in our tumormodel. Moreover, oncogenic alleles
have been shown to induce Nrf2 (DeNicola et al., 2011), and mu-
tations in KEAP1 can be detected in cancer cells, leading to
constitutive Nrf2 activation (Padmanabhan et al., 2006; Shibata
et al., 2008; Sjo¨blom et al., 2006). Future studies will clarify the
kinetics of Nrf2 and IL-17D induction during tumor formation.
Finally, it is clear that cancers display metabolic and oxidative
stress while also demonstrating an inflammatory component. In
fact, these characteristics of cancer have been touted as ‘‘next
generation hallmarks’’ (Hanahan and Weinberg, 2011). Based
on our findings, it is tempting to conclude that the Nrf2/IL-17D
pathway represents an important molecular bridge that con-
nects two hallmarks of cancer—inflammation and oxidative
stress.
EXPERIMENTAL PROCEDURES
Transcription Factor Binding Analysis
Sequences for mouse and human il17d genes were analyzed for the presence
of antioxidant responsive elements (ARE) (50-TGAcTCAGCa-30), a sequence to
which the Nrf2-sMAF heterodimer is known to bind (Nguyen et al., 2003). ARE
sequences identified in mouse and human il17d genes are listed in Table S1.
Cell Lines
MCA-induced sarcoma cell lines were generated from primary tumors and
expanded in vitro until at least the second passage before freezing. For exper-
imentation, tumor cell lines were thawed from early passages and grown in
RPMI 1640 (GIBCO) supplemented with 10% FCS (Atlanta Biologics) as previ-
ously described (O’Sullivan et al., 2012). Other tumor cell lines used—Ramos,
B16, LLC—were cultured similarly. Primary-derived mouse embryonic fibro-
blasts were derived from fetuses 12.5–13.5 days p.c. (as described in Conner,
2001a, 2001b).
Nrf2 Activation and Knockdown
Nrf2 was activated in cell lines in vitro with either tert-butylhydroquinone
(Spectrum) or H2O2 (Fisher). tBHQ was used at 50 mM in DMSO, and H2O2
was used at 10 mM for 0.5–1 hr before being washed out. Treated cells were
harvested at time points between 6 and 12 hr for analysis. Activation of Nrf2
in vivo was adapted from methods described by (Scha¨fer et al., 2014). For
in vivo Nrf2 activation, a cream containing 50mM tBHQ solubilized in DMSO
was mixed 1:1 (v/v) with Lanolin cream (Sigma) (controls were a 1:1 mixtureCell Reports 16, 2348–2358, August 30, 2016 2355
of DMSO:lanolin) and heated gently in a water bath to allow for mixing. The
mixture was allowed to cool overnight before use. Hair along the flank was
removed one day before the initiation of topical treatments. To knock down
Nrf2, a mixture of three siRNAs to nrf2 or control siRNA were used (Invitrogen)
(Fujita et al., 2011). siRNA was transfected into cells with Lipofectamine 2000
(Thermo Fisher) as recommended by the manufacturer. For shRNA knock-
down, five different shRNAs to nrf2 or control shRNA (Sigma) were co-trans-
fected with lentiviral plasmids into 293T cells using Lipofectamine 2000.
Virus-containing supernatant was used to transduce sarcoma and melanoma
tumor cell lines. Cells were grown in the presence of 10-40 mg/ml puromycin,
and nrf2 knockdown was confirmed with qPCR.
The Cancer Genome Atlas
Human tumor data were sourced from the TCGA analytical tool, UCSC Cancer
Genome Browser (http://cancergenome.nih.gov/). PANCAN normalized gene
expression data were used to partition tumors into roughly equally numbered
groups, compare transcript expression levels, and generate survival curves for
patients. For ARE-containing gene signature, the following genes were used:
hmox1, NADPH dehydrogenase (nqo)1, thioredoxin reductase (txnrd)1, gluta-
thione S-transferase-alpha (gsta)4, -mu (gstm) 1 and 3, sulfiredoxin (srxn) 1,
epoxide hydrolase (ephx)1, and alsin Rho guanine nucleotide exchange factor
(als)2. For analyzing NK cell metagenes, the expression Z scores from RNA-
seq for the genes perforin1, granzyme B, NKG2D, and natural cytotoxicity
triggering receptor1 were added up and used as ‘‘NK score’’ (approximation
of the presence of NK cells).
Mice
C57BL/6-strain WT, C57BL/63129-strain WT, B6-Rag2tm1.1Cgn (rag2/), B6-
Rag2tm1Fwa II2rgtm1Wjl (rag2/ gc/), B6-Il17dtm1Lex/Mmucd (il17d/) (UC
Davis MMRC), and B6-Nfe2l2tm1Ywk/J (nrf2/) (Jackson) were used for
studies in this work. To control for microbiota-influenced immunity disparities,
WT mice were bred for at least one generation in house before use. Rag2/
and Rag2/ gc/ colonies are maintained and in routine use in our lab.
Il17d/ and nrf2/ mice were obtained from UC Davis MMRC and Jackson
Laboratory, respectively. Mice were backcrossed to a C57/Bl6 background for
several generations until >99% pure. All mouse experiments were approved
by the University of California, San Diego (UCSD) Institutional Animal Care
and Use Committee (IACUC protocol #S06201) using amarker assisted selec-
tion (i.e., ‘‘speed congenic’’) approach. Mouse genomes were assessed at the
DartMouse Speed Congenic Core Facility at the Geisel School of Medicine at
Dartmouth. DartMouse uses the Illumina GoldenGate Genotyping Assay to
interrogate 1449 SNPs spread throughout the genome. The raw SNP data
were analyzed using DartMouse’s SNaP-Map andMap-Synth software, allow-
ing the determination for each mouse of the genetic background at each SNP
location. Genetic background at the final backcross generation was deter-
mined to be >99% for the desired C57BL/6 background. nrf2 genotyping
was performed as recommended (Jackson Laboratory), and il17d genotypes
from tail biopsies were determined using real-time PCR (Transnetyx).
Tumorigenesis and Tumor Transplantations
Primary tumorigenesis was performed as previously described (O’Sullivan
et al., 2012; Shankaran et al., 2001). MCA was dissolved in corn oil (Sigma)
prior to instillation. To induce primary tumors, 5-mg or 25-mg doses of MCA
were injected subcutaneously along a single flank. Tumor development was
monitored and measured weekly between 2 and 6 months post MCA instilla-
tion. Tumors were harvested for cell line generation and RNA when tumors
achieved an average diameter of 25 mm. For transplantation studies, tumor
cell lines were trypsinized, washed with cold PBS three times, and injected
subcutaneously along the flanks of mice (previously described in O’Sullivan
et al., 2012). Hair was removed from the flanks of mice at least 1 day prior to
transplantation. Tumor progression was assessed by averaging the greatest
two diameter measurements of the tumor.
Viral Infections
VV Western Reserve was kindly donated by the Dr. Ananda Goldrath (UCSD)
andMCMVSmithStrain byDr. Elina Zuniga (UCSD). Primary fibroblasts or tumor
cell lines were incubated with 1 3 105 pfu of MCMV or VV, respectively, per2356 Cell Reports 16, 2348–2358, August 30, 20164 3 105 cells for 2 hr, washed and harvested after 24 hr. Viral titers following
VV infection were determined by plaque assays on Vero cells (kindly donated
by Dr. Elina Zuniga). In vivo, age- and sex-matched 8- to 12-week-old C57Bl/6
WT or il17d/ mice were infected with VV by scarification at 1 3 105 or 1 3
106 pfu. VV scars were monitored daily and expressed as the average of the
two maximum scar diameters. For MCMV, mice were infected with 3 3 105
pfu/mouse intraperitoneally (i.p.) and weighed daily for disease progression.
Antibodies and FACS Analysis
Tumor tissues were digested bothmechanically by chopping with razor blades
and chemically with 1 mg/ml type IA collagenase (Sigma-Aldrich) for 30 min at
37C. Following digestion, cell suspensions were washed, filtered, and stained
as previously described (O’Sullivan et al., 2012). The following antibodies were
used: Ly6C (ER-MP20, Serotec), MHCII (M5/114 15.2, eBioscience), Ly6G
(1A8, Biolegend), CD8 (53-6.7, eBioscience), CD44 (IM7, Biolegend), CD3
(17A.2, Biolegend), CD4 (GK1.5, Biolegend), CD69 (H1.2F3, Biolegend), Gran-
zyme B (NGZB, eBioscience), IFNg (XMG 1.2, Biolegend), TCRb (H57-597,
Biolegend), B220 (RA3-6B2, eBioscience), NK1.1 (PK136, Biolegend),
CD11b (M1/70, eBioscience), and CD45 (30-F11, Biolegend). Stained cell sus-
pensions were analyzed on a BD FACS CANTO II (BD Biosciences).
Western Blot
Cells were lysed in 43 sample buffer containing SDS (Bio-Rad) and b-mercap-
toethanol (Sigma) before boiling at 95C for 5 min. Samples were run on SDS-
PAGE gels (Bio-Rad), and expression of Nrf2 was analyzed by western blotting
using anti-Nrf2 (C-20, Santa Cruz Biotech). b-actin (A5441, Sigma-Aldrich) was
used as loading control. Blotted bands were quantified with CS6 Photoshop
imaging software.
Immunohistochemistry
Tissues were fixed in 10% formalin (Sigma-Aldrich) for 24 hr before embedding
in paraffin. Sections were stained with a-Nrf2 (C-20) by the UCSD Core Histol-
ogy and Immunohistochemistry service using the Ventana Discovery Ultra
(Roche). Slides were imaged on a Leica DM 2500 microscope and photo-
graphed with a Leica DFC 420 digital camera.
Chromatin Immunoprecipitation
ChIP for Nrf2 was performed as described previously (DeNicola et al., 2011).
Following activation of Nrf2 with tBHQ, cells were fixed in 1% formaldehyde
for 10 min at room temperature, quenched with 0.125 M glycine for 5 min at
room temperature, washed with cold PBS, and resuspended in lysis buffer
(1%SDS, 10mMEDTA [pH 8], 50mMTris-HCL[ pH 8]), fresh protease inhibitor
cocktail for 5 min on ice. To generate chromatin fragments of 200 bp, cell
lysates were sonicated on ice for 15 cycles (15-s on, 45-s off) and pelleted
by centrifugation at 13,000 rpm for 5 min. Protein A Dynabeads (Life Technol-
ogies), pre-blocked in 0.5%BSA in PBS (w/v), were incubated with 8 mg a-Nrf2
(C-20) or normal rabbit IgG (sc-2027, Santa Cruz Biotech) overnight at 4C and
then washed with additional blocking buffer and RIPA. To immunoprecipitate
Nrf2-chromatin complexes, conjugated Dynabeads were mixed with soni-
cated lysate—diluted 1:9 in dilution buffer with protease inhibitors—and
allowed to rotate overnight at 4C. Immunoprecipitates were processed as
suggested by the Dynabeads manufacturer (Life Technologies) and purified
using the QiaQuick PCR DNA kit (QIAGEN). qPCR sequences used for ChIP
samples appear in Table S3.
qPCR
RNA was isolated with Trizol (Ambion) and converted to cDNA (Applied
Biosystems High-Capacity cDNA Reverse Transcription Kit). qPCRs were
prepared with 23 Universal SYBR Green Master Mix (Applied Biosystems)
and performed on Bio-Rad CFX96 (Bio-Rad) machine. The following primer
sequences were used: HPRT (forward: 50-GCTTGCTGGTGAAAAGGACC
TCTCGAAG-30; reverse: 50-CCCTGAAGTACTCATTATAGTCAAGGGCAT-30),
IL-17D (forward: 50-AGCTTGTCCATGCTGGAGTT-30; reverse: 50-CTCTACG
GGGAGGAGGACTT-30 ), HMOX-1 (forward: 50-TGAAGGAGGCCACCAAGG
AGG-30; reverse: 50-AGAGGTCACCCAGGTAGCGGG-30), and Keratin 18 (for-
ward: 50-AGCCATTACTTCAAGATCATC-30; reverse: 50-CTCTGTCTCATAC
TTGACTCT-30).
Statistical Analysis
Statistical significance was determined by the Welch’s t test, using a two-
tailed analysis, the log-rank test, or the repeated-measures ANOVA test with
the InStat 3.0 software (GraphPad). Error bars are depicted using SEM. All ex-
periments were repeated at least twice (*p < 0.05, **p < 0.01, ***p < 0.001 in all
data shown).
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